Focus on Crohn's disease

被引:0
|
作者
Klotz, Caroline [1 ]
Dhooge, Marion [1 ,2 ]
Oudjit, Ammar [3 ]
Barret, Maximilien [1 ,2 ]
Beuvon, Frederic [4 ]
Chaussade, Stanislas [1 ,2 ]
Coriat, Romain [1 ,2 ]
Abitbol, Vered [1 ]
机构
[1] Hop Cochin, AP HP, Serv Gastroenterol, F-75674 Paris, France
[2] Univ Paris 05, Fac Med, F-75014 Paris, France
[3] Hop Cochin, AP HP, Serv Radiol, F-75014 Paris, France
[4] Hop Cochin, AP HP, Serv Anatomopathol, F-75014 Paris, France
来源
PRESSE MEDICALE | 2015年 / 44卷 / 04期
关键词
CLINICAL-RESPONSE; INFLIXIMAB; THERAPY; MAINTENANCE; AZATHIOPRINE; ADALIMUMAB; BIOMARKERS; REMISSION; EFFICACY; ANTIBODY;
D O I
10.1016/j.lpm.2014.07.028
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Crohn's disease is an inflammatory bowel disease that affects the entire digestive tract, from the mouth to the anus. The inflammatory disease is transmural and may be complicated by abscesses, fistulas, strictures. Budesonide is used as first-line treatment for a first episode of ileitis. Thiopurines and methotrexate are used as immunosuppressive maintenance therapy. Anti-tumour necrosis factors (TNF) alpha therapy is used as induction and maintenance therapy in case of severe flares or corticodependence. Combination of immunosuppressive therapy and anti-TNF-alpha (combotherapy) prevents the appearance of specific anti drug antibodies. Combotherapy is used in case of severe disease. The goal of the treatment is to achieve clinical remission, endoscopic mucosal healing, and to prevent the occurrence of complications such as strictures, fistulas or abscesses. Anoperineal lesions are found in 10% of the patients at diagnosis. Surgical treatment is indicated for severe medical treatment-resistant patients or complications such as symptomatic stenosis, fistula or abscess unresponsive to medical treatment or immediately complicated.
引用
收藏
页码:411 / 417
页数:7
相关论文
共 50 条
  • [1] Adalimumab Safety in Global Clinical Trials of Patients with Crohn's Disease
    Colombel, Jean-Frederic
    Sandborn, William J.
    Panaccione, Remo
    Robinson, Anne M.
    Lau, Winnie
    Li, Ju
    Cardoso, Alexandra T.
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (09) : 1308 - 1319
  • [2] Prevention of postoperative recurrence of Crohn's disease by Adalimumab: a case series
    Savarino, Edoardo
    Dulbecco, Pietro
    Bodini, Giorgia
    Assandri, Lorenzo
    Savarino, Vincenzo
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2012, 24 (04) : 468 - 470
  • [3] A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab
    Yokoyama, Kaoru
    Yamazaki, Kiyotaka
    Katafuchi, Miiko
    Ferchichi, Sameh
    ADVANCES IN THERAPY, 2016, 33 (11) : 1947 - 1963
  • [4] Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients
    Peters, Charlotte P.
    Eshuis, Emma J.
    Toxopeus, Florien M.
    Hellemons, Merel E.
    Jansen, Jeroen M.
    D'Haens, Geert R. A. M.
    Fockens, Paul
    Stokkers, Pieter C. F.
    Tuynman, Hans A. R. E.
    van Bodegraven, Adriaan A.
    Ponsioen, Cyriel Y.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 (08) : 866 - 875
  • [5] Cost-Effectiveness Analysis of Parenteral Methotrexate for the Treatment of Crohn's Disease
    Mlcoch, Tomas
    Decker, Barbora
    Dolezal, Tomas
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2021, 19 (04) : 593 - 604
  • [6] Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn's Disease
    Nichita, Cristina
    Stelle, Marc
    Vavricka, Stephan
    Ali, Abdou El-Wafa
    Ballabeni, Pierluigi
    de Saussure, Philippe
    Straumann, Alex
    Rogler, Gerhard
    Michetti, Pierre
    DIGESTION, 2010, 81 (02) : 78 - 85
  • [7] Anti-TNF and Crohn's Disease: When Should We Stop?
    Louis, Edouard
    Belaiche, Jacques
    Reenaers, Catherine
    CURRENT DRUG TARGETS, 2010, 11 (02) : 148 - 151
  • [8] Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease
    Mastronardi, Mauro
    Curlo, Margherita
    Cavalcanti, Elisabetta
    Burattini, Osvaldo
    Cuppone, Renato
    Tauro, Romina
    De Santis, Stefania
    Serino, Grazia
    Pesole, Pasqua Letizia
    Stasi, Elisa
    Caruso, Maria Lucia
    Donghia, Rossella
    Guerra, Vito
    Giorgio, Pietro
    Chieppa, Marcello
    FRONTIERS IN MEDICINE, 2019, 6
  • [9] Adalimumab Treatment in Children with Refractory Crohn's Disease
    Rosenbach, Yoram
    Hartman, Corina
    Shapiro, Rivka
    Hirsch, Akiva
    Avitzur, Yaron
    Shamir, Raanan
    DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (03) : 747 - 753
  • [10] Methotrexate for induction of remission in refractory Crohn's disease
    McDonald, John W. D.
    Tsoulis, David J.
    MacDonald, John K.
    Feagan, Brian G.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (12):